ID

31063

Descrizione

Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01196234

collegamento

https://clinicaltrials.gov/show/NCT01196234

Keywords

versioni (1)
  1. 16/07/18 16/07/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

16 luglio 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Non Small Cell Lung Cancer NCT01196234

Inglese

Eligibility Non Small Cell Lung Cancer NCT01196234

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
more than 18 years of age
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
histologically documented non-small cell lung cancer with metastasis (stage iv) or locally advanced (stage iiib) with malignant effusion.
Descrizione

Non-small cell lung cancer metastatic TNM clinical staging | Non-Small Cell Lung Carcinoma Advanced Locally TNM clinical staging | Effusion Malignant

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0278987
UMLS CUI [1,2]
C3258246
UMLS CUI [2,1]
C0007131
UMLS CUI [2,2]
C0205179
UMLS CUI [2,3]
C1517927
UMLS CUI [2,4]
C3258246
UMLS CUI [3,1]
C0013687
UMLS CUI [3,2]
C0205282
at least 1 measurable lesion as defined by recist1.0. all target lesions must have a unidirectional diameter of at least 1cm. baseline measurements must be compared within 4 weeks prior to enrollment.
Descrizione

Measurable lesion Quantity | Target Lesion Diameter Linear

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
UMLS CUI [2,1]
C2986546
UMLS CUI [2,2]
C1301886
UMLS CUI [2,3]
C0205132
ecog ps 0-2
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
at least 1 week since the last radiotherapy. patients must have recovered from all acute toxicities from radiotherapy.
Descrizione

Therapeutic radiology procedure In the past | Toxicity Due to Therapeutic radiology procedure | Patient recovered

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C1444637
UMLS CUI [2,1]
C0600688
UMLS CUI [2,2]
C0678226
UMLS CUI [2,3]
C1522449
UMLS CUI [3]
C1115804
patients must have adequate hematologic, renal and liver function as defined by hb > 9g/dl, neutrophils > 1000/mm3, platelets > 50,000/mm3, creatinine < 2mg/dl, and ast (sgot) and/or alt (sgpt) < 5 x unl (upper normal limit).
Descrizione

Hematologic function | Renal function | Liver function | Hemoglobin measurement | Neutrophil count | Platelet Count measurement | Creatinine measurement, serum | Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
UMLS CUI [4]
C0518015
UMLS CUI [5]
C0200633
UMLS CUI [6]
C0032181
UMLS CUI [7]
C0201976
UMLS CUI [8]
C0201899
UMLS CUI [9]
C0201836
willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.
Descrizione

Protocol Compliance

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0525058
written and voluntary informed consent understood, signed and dated.
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with tumor harboring egfr mutation.
Descrizione

Tumor Associated with EGFR gene mutation

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C0332281
UMLS CUI [1,3]
C3266992
prior systemic therapy for nsclc
Descrizione

Systemic therapy Non-Small Cell Lung Carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0007131
non-smoking patients with adenocarcinoma. but if those patients show wild type egfr, they are eligible to this study.
Descrizione

Non-smoker | Adenocarcinoma | Patients EGFR gene Wild Type Eligible

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0337672
UMLS CUI [2]
C0001418
UMLS CUI [3,1]
C0030705
UMLS CUI [3,2]
C1414313
UMLS CUI [3,3]
C1883559
UMLS CUI [3,4]
C1548635
symptomatic brain metastasis. brain metastases stable < 2 weeks before dosing or requiring concurrent steroid treatment or with clinical symptoms.
Descrizione

Metastatic malignant neoplasm to brain Symptomatic | Metastatic malignant neoplasm to brain Stable | Metastatic malignant neoplasm to brain Requirement Steroid therapy | Metastatic malignant neoplasm to brain Symptoms Clinical

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0231220
UMLS CUI [2,1]
C0220650
UMLS CUI [2,2]
C0205360
UMLS CUI [3,1]
C0220650
UMLS CUI [3,2]
C1514873
UMLS CUI [3,3]
C0149783
UMLS CUI [4,1]
C0220650
UMLS CUI [4,2]
C1457887
UMLS CUI [4,3]
C0205210
major surgery within 3 weeks prior to study enrollment.
Descrizione

Major surgery

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0679637
previous (less than 3 years ago) or current malignancies at sites other than curatively treated in situ carcinoma of cervix, or basal or squamous cell carcinoma of the skin.
Descrizione

Malignant Neoplasms | Exception Curative treatment Carcinoma in situ of uterine cervix | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Squamous cell carcinoma of skin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1273390
UMLS CUI [2,3]
C0851140
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1273390
UMLS CUI [3,3]
C0007117
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1273390
UMLS CUI [4,3]
C0553723
severe medical illness or active infection that would impair the ability to receive gefitinib.
Descrizione

Illness Severe | Communicable Disease | Gefitinib Receive Impaired

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205082
UMLS CUI [2]
C0009450
UMLS CUI [3,1]
C1122962
UMLS CUI [3,2]
C1514756
UMLS CUI [3,3]
C0221099
pregnancy or breast feeding.
Descrizione

Pregnancy | Breast Feeding

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Ritorna all'inizio della pagina

Similar models

Eligibility Non Small Cell Lung Cancer NCT01196234

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
more than 18 years of age
boolean
C0001779 (UMLS CUI [1])
Non-small cell lung cancer metastatic TNM clinical staging | Non-Small Cell Lung Carcinoma Advanced Locally TNM clinical staging | Effusion Malignant
Item
histologically documented non-small cell lung cancer with metastasis (stage iv) or locally advanced (stage iiib) with malignant effusion.
boolean
C0278987 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0007131 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1517927 (UMLS CUI [2,3])
C3258246 (UMLS CUI [2,4])
C0013687 (UMLS CUI [3,1])
C0205282 (UMLS CUI [3,2])
Measurable lesion Quantity | Target Lesion Diameter Linear
Item
at least 1 measurable lesion as defined by recist1.0. all target lesions must have a unidirectional diameter of at least 1cm. baseline measurements must be compared within 4 weeks prior to enrollment.
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C2986546 (UMLS CUI [2,1])
C1301886 (UMLS CUI [2,2])
C0205132 (UMLS CUI [2,3])
ECOG performance status
Item
ecog ps 0-2
boolean
C1520224 (UMLS CUI [1])
Therapeutic radiology procedure In the past | Toxicity Due to Therapeutic radiology procedure | Patient recovered
Item
at least 1 week since the last radiotherapy. patients must have recovered from all acute toxicities from radiotherapy.
boolean
C1522449 (UMLS CUI [1,1])
C1444637 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,3])
C1115804 (UMLS CUI [3])
Hematologic function | Renal function | Liver function | Hemoglobin measurement | Neutrophil count | Platelet Count measurement | Creatinine measurement, serum | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
patients must have adequate hematologic, renal and liver function as defined by hb > 9g/dl, neutrophils > 1000/mm3, platelets > 50,000/mm3, creatinine < 2mg/dl, and ast (sgot) and/or alt (sgpt) < 5 x unl (upper normal limit).
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
C0518015 (UMLS CUI [4])
C0200633 (UMLS CUI [5])
C0032181 (UMLS CUI [6])
C0201976 (UMLS CUI [7])
C0201899 (UMLS CUI [8])
C0201836 (UMLS CUI [9])
Protocol Compliance
Item
willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.
boolean
C0525058 (UMLS CUI [1])
Informed Consent
Item
written and voluntary informed consent understood, signed and dated.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Tumor Associated with EGFR gene mutation
Item
patients with tumor harboring egfr mutation.
boolean
C0027651 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C3266992 (UMLS CUI [1,3])
Systemic therapy Non-Small Cell Lung Carcinoma
Item
prior systemic therapy for nsclc
boolean
C1515119 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
Non-smoker | Adenocarcinoma | Patients EGFR gene Wild Type Eligible
Item
non-smoking patients with adenocarcinoma. but if those patients show wild type egfr, they are eligible to this study.
boolean
C0337672 (UMLS CUI [1])
C0001418 (UMLS CUI [2])
C0030705 (UMLS CUI [3,1])
C1414313 (UMLS CUI [3,2])
C1883559 (UMLS CUI [3,3])
C1548635 (UMLS CUI [3,4])
Metastatic malignant neoplasm to brain Symptomatic | Metastatic malignant neoplasm to brain Stable | Metastatic malignant neoplasm to brain Requirement Steroid therapy | Metastatic malignant neoplasm to brain Symptoms Clinical
Item
symptomatic brain metastasis. brain metastases stable < 2 weeks before dosing or requiring concurrent steroid treatment or with clinical symptoms.
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0220650 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
C0220650 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
C0149783 (UMLS CUI [3,3])
C0220650 (UMLS CUI [4,1])
C1457887 (UMLS CUI [4,2])
C0205210 (UMLS CUI [4,3])
Major surgery
Item
major surgery within 3 weeks prior to study enrollment.
boolean
C0679637 (UMLS CUI [1])
Malignant Neoplasms | Exception Curative treatment Carcinoma in situ of uterine cervix | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Squamous cell carcinoma of skin
Item
previous (less than 3 years ago) or current malignancies at sites other than curatively treated in situ carcinoma of cervix, or basal or squamous cell carcinoma of the skin.
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1273390 (UMLS CUI [2,2])
C0851140 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
C0007117 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C1273390 (UMLS CUI [4,2])
C0553723 (UMLS CUI [4,3])
Illness Severe | Communicable Disease | Gefitinib Receive Impaired
Item
severe medical illness or active infection that would impair the ability to receive gefitinib.
boolean
C0221423 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
C1122962 (UMLS CUI [3,1])
C1514756 (UMLS CUI [3,2])
C0221099 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
pregnancy or breast feeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial